The BMP‐ACVR1 axis is a universal mechanism for the efficacy of PRC2 inhibitors in B‐cell lymphoma, with the example of the inhibitors used in this study, such as MAK683, EPZ6438 and HJM‐353. This evidence concerns the gene ACVR1 and B-cell non-Hodgkin lymphoma.